FDA Approves Etcamah Plus CDK4/6 Inhibitor for ESR1-Mutated Breast CancerByQuincy AttobrahSeptember 4th 2026
Why Personalized Cancer Treatment Doesn’t Always Work as ExpectedByKaitlyn M. Le,Dr. Miguel Gonzalez-VelezSeptember 4th 2026
Prostate Cancer Treatments in the FDA Pipeline: What Could Come NextBySpencer FeldmanSeptember 4th 2026
Thyroid Cancer: What Patients Should Know About Treatment, Surveillance and Life AfterByDr. Neeta ErinjeriSeptember 4th 2026
